پومالیدوماید

Also known as CC-4047, IMID-3, Imnovid®, Pomalyst®, CC 4047, 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide, 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione, 4-Aminothalidomide

Pomalidomide, sold under the brand name Pomalyst among others, is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. It inhibits angiogenesis, the formation of new blood vessels.

Key facts

Drug.width: 200
Drug.image: Pomalidomide enantiomers.svg
Drug.image_class: skin-invert-image
Drug.chirality: Racemic mixture
Drug.tradename: Pomalyst, others
Drug.MedlinePlus: a613030
Drug.DailyMedID: Pomalidomide
Drug.pregnancy_AU: X
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: L04
Drug.ATC_suffix: AX06
Drug.legal_AU: S4
Drug.legal_BR: C3
Drug.legal_CA: Rx-only
Drug.legal_UK: POM
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.bioavailability: 73% (at least)

via Wikipedia infobox

Chemical data

Formula: C13H11N3O4
Molecular weight: 273.24 g/mol
IUPAC name: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
InChIKey: UVSMNLNDYGZFPF-UHFFFAOYSA-N
XLogP: 0.2
Polar surface area: 110 Å²
H-bond donors: 2
H-bond acceptors: 5
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2013
Admin. routes: oral
Indications: myeloproliferative disorder, immune system disease, systemic scleroderma, multiple myeloma

via ChEMBL · EBI

Research

1,522 papers

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.The Lancet. Oncology · 2021
Pomalidomide.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2014
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.The New England journal of medicine · 2024
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.Lancet (London, England) · 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.The Lancet. Oncology · 2019

via PubMed

Wikidata facts

Subclass of: chemical compound
Mass: 273.074956
Has use: medication

Show 6 more facts

defined daily dose: 3
chemical formula: C₁₃H₁₁N₃O₄
Commons category: Pomalidomide
canonical SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
World Health Organisation international non-proprietary name: pomalidomide
subject has role: angiogenesis inhibitor

Sources (5)

via Wikidata · CC0

Available in 14 languages

via Wikidata sitelinks · CC0